CLINICAL TRIALS PROFILE FOR LEVALBUTEROL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for LEVALBUTEROL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00064389 ↗ | Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma | Completed | Sunovion | Phase 3 | 2003-01-01 | The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects with asthma. |
| NCT00073814 ↗ | Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma | Completed | Sunovion | Phase 3 | 2002-12-01 | Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects with Asthma |
| NCT00073827 ↗ | Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma | Completed | Sunovion | Phase 3 | 2002-05-01 | The primary purpose of this study was to investigate the efficacy of levalbuterol compared to a placebo and compared to albuterol in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID). |
| NCT00073840 ↗ | Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma | Completed | Sunovion | Phase 3 | 2002-12-01 | The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID). |
| NCT00124176 ↗ | Continuous Levalbuterol for Treatment of Status Asthmaticus in Children | Completed | Sunovion | Phase 4 | 2004-04-01 | This study will use a randomized, double-blind, controlled trial design in order to assess the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when delivered continuously in a high-dose regimen for children with severe exacerbations of asthma. Primary hypothesis - Children with severe asthma receiving continuous levalbuterol will have a shorter duration of continuous therapy as compared to racemic albuterol. Secondary hypotheses - Children receiving continuous levalbuterol will have improved lung function measured by forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol. - Children receiving continuous levalbuterol will have improved clinical asthma score as compared to racemic albuterol. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LEVALBUTEROL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for LEVALBUTEROL HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for LEVALBUTEROL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for LEVALBUTEROL HYDROCHLORIDE
Sponsor Name
